Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, China; Hubei Key Laboratory of Metabolic and Chronic Diseases, Wuhan, Hubei, 430060, China.
Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, Hubei, 430060, China; Hubei Key Laboratory of Metabolic and Chronic Diseases, Wuhan, Hubei, 430060, China.
Free Radic Biol Med. 2023 Aug 20;205:275-290. doi: 10.1016/j.freeradbiomed.2023.06.004. Epub 2023 Jun 17.
Ferroptosis has been suggested to involve in doxorubicin (DOX)-induced cardiotoxicity. However, the underlying mechanisms and regulatory targets of cardiomyocyte ferroptosis remains to be understood. This study demonstrated that the up-regulation of ferroptosis associated proteins genes were accompanied with the down-regulation of AMPKα2 phosphorylation in DOX treated mouse heart or neonatal rat cardiomyocytes (NRCMs). AMPKα2 knockout (AMPKα2-/-) significantly exacerbated mouse cardiac dysfunction, increased mortality, promoting ferroptosis associated mitochondrial injuries, enhanced ferroptosis associated proteins and genes expression, and lead to accumulation of lactate dehydrogenase (LDH) and malondialdehyde (MDA) in mouse serum and hearts respectively. Ferrostatin-1 administration markedly improved cardiac function, decreased mortality, inhibited mitochondrial injuries and ferroptosis associated proteins and genes expression, and depressed accumulation of LDH and MDA in DOX treated AMPKα2-/- mouse. Moreover, Adeno-associated virus serotype 9 AMPKα2 (AAV9-AMPKα2) or AICAR treatment mediated AMPKα2 activation could significantly improve cardiac function and depress ferroptosis in mouse. AMPKα2 activation or silence could also inhibit or promote ferroptosis associated injuries in DOX treated NRCMs respecitively. Mechanistically, AMPKα2/ACC mediated lipid metabolism has been suggested to involve in regulating DOX-treatment induced ferroptosis other than mTORC1 or autophagy dependent pathway. The metabolomics analysis exhibited that AMPKα2-/- significantly enhanced accumulation of polyunsaturated fatty acids (PFAs), oxidized lipid, and phosphatidylethanolamine (PE). Finally, this study also demonstrated that metformin (MET) treatment could inhibit ferroptosis and improve cardiac function via activating AMPKα2 phosphorylation. The metabolomics analysis exhibited that MET treatment significantly depressed PFAs accumulation in DOX treated mouse hearts. Collectively, this study suggested that AMPKα2 activation might protect against anthracycline chemotherapeutic drugs mediated cardiotoxicity via inhibiting ferroptosis.
铁死亡已被认为参与阿霉素(DOX)诱导的心脏毒性。然而,心肌细胞铁死亡的潜在机制和调控靶点仍有待阐明。本研究表明,在 DOX 处理的小鼠心脏或新生大鼠心肌细胞(NRCMs)中,铁死亡相关蛋白基因的上调伴随着 AMPKα2 磷酸化的下调。AMPKα2 敲除(AMPKα2-/-)显著加重了小鼠心脏功能障碍,增加了死亡率,促进了铁死亡相关的线粒体损伤,增强了铁死亡相关蛋白和基因的表达,并导致乳酸脱氢酶(LDH)和丙二醛(MDA)在小鼠血清和心脏中的积累。铁死亡抑制剂(Ferrostatin-1)给药显著改善了心脏功能,降低了死亡率,抑制了线粒体损伤和铁死亡相关蛋白和基因的表达,降低了 DOX 处理的 AMPKα2-/-小鼠血清和心脏中 LDH 和 MDA 的积累。此外,腺相关病毒血清型 9 AMPKα2(AAV9-AMPKα2)或 AICAR 处理介导的 AMPKα2 激活可以显著改善心脏功能并抑制 DOX 处理的小鼠中铁死亡。AMPKα2 的激活或沉默也分别抑制或促进 DOX 处理的 NRCMs 中铁死亡相关损伤。机制上,AMPKα2/ACC 介导的脂质代谢可能参与调节 DOX 处理诱导的铁死亡,而不是 mTORC1 或自噬依赖性途径。代谢组学分析表明,AMPKα2-/-显著增加了多不饱和脂肪酸(PFAs)、氧化脂质和磷脂酰乙醇胺(PE)的积累。最后,本研究还表明,二甲双胍(MET)治疗可以通过激活 AMPKα2 磷酸化来抑制铁死亡和改善心脏功能。代谢组学分析表明,MET 处理显著降低了 DOX 处理的小鼠心脏中 PFAs 的积累。总之,本研究表明,AMPKα2 的激活可能通过抑制铁死亡来保护心脏免受蒽环类化疗药物介导的心脏毒性。